Gene DSCC1 is a Potential Biomarker in Pan-cancer

Jialing Jiang, Xiaolong Yan, Dan Huang, Jieyu Chen, Xiaodan HaoJournal of Contemporary Medical Practice 2025 · DOI

TL;DR

This pan-cancer study identifies DSCC1 (DNA replication and sister chromatid cohesion 1) as a potent biomarker for poor prognosis across a wide array of human malignancies. Beyond its known role in cell division, the research reveals that DSCC1 significantly influences the tumor immune microenvironment and genomic stability, making it a promising candidate for both diagnostic screening and targeted immunotherapy.

What Problem Does This Paper Address?

Despite advancements in surgery, radiation, and chemotherapy, cancer remains a leading cause of global mortality. Immunotherapy has offered a breakthrough, yet many patients do not respond to it due to the complex and heterogeneous nature of tumors.

The authors focus on the gap in our understanding of DSCC1. While it is known to be a component of the alternative replication factor C (RFC) complex—essential for DNA replication and sister chromatid cohesion—its broader role across different cancer types (pan-cancer) and its specific impact on tumor immunity remained obscure. By mapping DSCC1’s behavior across dozens of cancer types, the researchers sought to determine if it could serve as a universal indicator of disease progression and a target for new therapies.

Methods

The study utilized a comprehensive bioinformatic pipeline to analyze DSCC1 across various dimensions:

  • Differential Expression: Comparing DSCC1 mRNA and protein levels between tumor and normal tissues using TIMER 2.0, GEPIA 2.0, and UALCAN.
  • Survival Analysis: Employing Kaplan-Meier curves and univariate Cox regression to link DSCC1 levels to Overall Survival (OS), Disease-Specific Survival (DSS), and Progression-Free Interval (PFI).
  • Immune Landscape Mapping: Correlating gene expression with immune checkpoints, tumor-infiltrating immune cells (TIICs), and stromal/immune scores (via the ESTIMATE algorithm).
  • Genomic Stability Analysis: Investigating relationships with Tumor Mutational Burden (TMB), Microsatellite Instability (MSI), and stemness scores (DNAss/RNAss).
  • Pathway Enrichment: Using Gene Set Enrichment Analysis (GSEA) and Protein-Protein Interaction (PPI) networks to identify the biological "machinery" DSCC1 interacts with.

Datasets

The researchers integrated data from several high-profile repositories:

  • TCGA (The Cancer Genome Atlas): For primary tumor gene expression and clinical data.
  • GTEx (Genotype-Tissue Expression): For normal tissue baseline expression.
  • CPTAC (Clinical Proteomic Tumor Analysis Consortium): For validating findings at the protein level.
  • TIMER (Tumor Immunity Estimation Resource): For analyzing immune cell infiltration.

Key Insights and Ideas

  • A "Double-Edged" Cell Cycle Regulator: While DSCC1 is fundamentally a cell cycle gene (enriched in E2F targets and G2/M checkpoints), its upregulation is a near-universal feature of aggressive tumors, appearing in 22 different cancer types.
  • The Immune Connection: One of the most significant findings is that DSCC1 isn't just a marker of rapid division; it correlates with the expression of major immune checkpoints like PD-L1, LAG3, and CD276. This suggests that high DSCC1 levels might help tumors evade the immune system.
  • Genomic Instability Driver: High DSCC1 expression positively correlates with TMB and MSI in several cancers (e.g., lung and stomach adenocarcinoma). This implies that DSCC1 might either contribute to or be a byproduct of a "hyper-mutated" state that drives cancer evolution.
  • The Thymoma (THYM) Paradox: Interestingly, while high DSCC1 usually signals a poor prognosis, it correlates with better overall survival and higher immune infiltration in Thymoma. This highlights the importance of tissue-specific context in biomarker research.

Key Results

  • Upregulation: DSCC1 mRNA was significantly elevated in 22 tumors, including breast (BRCA), colon (COAD), and lung (LUAD) cancers.
  • Prognostic Power: High DSCC1 expression was a significant predictor of "dismal" overall survival in 15 different tumor types.
  • Protein Validation: UALCAN analysis confirmed that DSCC1 protein levels were significantly higher in 7 major cancers, including hepatocellular carcinoma and ovarian cancer.
  • Pathway Enrichment: GSEA confirmed that DSCC1 is critically involved in DNA replication and cell cycle regulation, physically interacting with proteins like Ctf18 and RFC subunits.

Limitations and Future Work

The authors acknowledge that this study is primarily bioinformatic. While the correlations are robust across massive datasets, the study lacks "wet lab" experimental validation.

  • Mechanistic Gaps: The exact biochemical pathways by which DSCC1 modulates the immune microenvironment remain theoretical.
  • Future Directions: The authors suggest that future research should involve in vitro and in vivo experiments to confirm these mechanisms. Additionally, clinical trials are needed to determine if DSCC1-targeted therapies can actually improve patient outcomes or if DSCC1 can be used to stratify patients for existing immunotherapies.

Summary updated

Abstract

Background: DNA replication and sister chromatid cohesion1 (DSCC1) is a component of the alternative replication factor C complex (RFC), which plays an important role in sister chromatid cohesion and regulates the cell cycle. DSCC1 is reported to have increased expression in tumor progression, but the underlying mechanisms of DSCC1 in tumor immunity remain obscure. Methods: Data were collected from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) project to obtain DSCC1 expression and clinicopathologically relevant data. Differential expression of DSCC1 and its association with prognosis, tumor microenvironment, immune infiltration, immune regulation, and genomic stability in various cancers were analyzed using R software. Results: The results of pan-cancer analysis showed that DSCC1 expression was elevated in 22 tumors. In 15 tumors, high expression of DSCC1 was observed to correlate with dismal overall survival. Furthermore, a correlation between DSCC1 expression and immune checkpoints was determined. In addition, DSCC1 expression was correlated with tumor-infiltrating immune cells, especially in Thymoma (THYM). Finally, gene set enrichment analysis (GSEA) demonstrated that DSCC1 is critically involved in tumor proliferation, immunity, and metabolism. Conclusions: High DSCC1 expression is found in many common tumors and is associated with poor prognosis. The gene is an essential factor in sister chromatid cohesion and may contribute to tumor progression by affecting the tumor immune microenvironment and genomic stability. DSCC1 has the potential to be a prognostic marker, and therapies targeting it may benefit patients.
BibTeX
@article{jiang2025gene,
  author = {Jialing Jiang and Xiaolong Yan and Dan Huang and Jieyu Chen and Xiaodan Hao},
  title = {{Gene DSCC1 is a Potential Biomarker in Pan-cancer}},
  journal = {Journal of Contemporary Medical Practice},
  year = {2025},
  doi = {10.53469/jcmp.2025.07(05).18},
}
Figure